Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
Reid W. Merryman(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Austin Kim(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Amanda F. Cashen(Washington University in St. Louis), Robin Joyce(Beth Israel Deaconess Medical Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Natasha Edwin(Washington University in St. Louis), Philippe Armand(Harvard University), Heather A. Jacene(Brigham and Women's Hospital), Matthew Chase(Brigham and Women's Hospital), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Brad S. Kahl(UW Health University Hospital), Nancy L. Bartlett(Washington University in St. Louis), Armin Ghobadi(Washington University in St. Louis), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Jad Bsat(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Robert Redd(Harvard University)
Cited by 58
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k